Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alpa Laboratories's share price for the quarter that ended in Mar. 2026 was ₹46.46. Alpa Laboratories's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 21 Mil. Therefore, Alpa Laboratories's market cap for the quarter that ended in Mar. 2026 was ₹978 Mil.
Alpa Laboratories's quarterly market cap
declined
from Sep. 2025 (₹1,862 Mil) to Dec. 2025 (₹1,635 Mil) and
declined
from Dec. 2025 (₹1,635 Mil) to Mar. 2026 (₹978 Mil).
Alpa Laboratories's annual market cap
increased
from Mar. 2024 (₹1,752 Mil) to Mar. 2025 (₹2,180 Mil) but then
declined
from Mar. 2025 (₹2,180 Mil) to Mar. 2026 (₹978 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alpa Laboratories's Enterprise Value for Today is ₹48 Mil.
Alpa Laboratories (NSE:ALPA) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alpa Laboratories Market Cap Related Terms
Alpa Laboratories Market Cap Historical Data
* Premium members only.
The historical data trend for Alpa Laboratories's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alpa Laboratories's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpa Laboratories Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alpa Laboratories's Market Cap distribution charts can be found below:
* The bar in red indicates where Alpa Laboratories's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alpa Laboratories's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpa Laboratories (NSE:ALPA) has a Market Cap of ₹1,431 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alpa Laboratories and its competitors. According to the industry distribution chart, Alpa Laboratories ranks #833 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Alpa Laboratories' Market Cap too high?
Alpa Laboratories' current Market Cap is ₹1,431 Mil. Based on the distribution chart, Alpa Laboratories ranks #833 out of 1022 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Alpa Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alpa Laboratories' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alpa Laboratories ranks #833 out of 1022 companies for Market Cap. This places Alpa Laboratories in the lower half of its industry. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Alpa Laboratories and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpa Laboratories's current Market Cap is ₹1,431 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpa Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Alpa Laboratories (NSE:ALPA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹92.80, compared to a current price of ₹67.55 — trading 27.2% below its estimated fair value. The current Market Cap is ₹1,431 Mil. Alpa Laboratories' overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Alpa Laboratories (NSE:ALPA), the current Market Cap is ₹1,431 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alpa Laboratories (NSE:ALPA) Overvalued in 2026?
Based on GuruFocus' analysis, Alpa Laboratories stock appears to be undervalued.
The current stock price of ₹67.55 is trading 27.2% below its estimated GF Value™ of ₹92.80.
GuruFocus considers Alpa Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:ALPA:
Market Cap: ₹1,431 Mil
GF Value™: ₹92.80 vs. price of ₹67.55 (27.2% below fair value)
No single metric tells the full story. See the NSE:ALPA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alpa Laboratories Ltd is an India-based pharmaceutical company. It operates in the drug and chemical business segment. The company manufactures and markets pharmaceuticals and related products. It sells products like liquid injection, dry powder injection, tablets, capsules, and ointments.
74GF Score
Get the complete analysis for NSE:ALPA
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALPA has been successfully added to your 
